GFAP and Alzheimer disease: In fact, 3-month μm‐PEA treatment markedly reduced astrocytic activation in 3xTg-AD mice, as demonstrated by the decrease in GFAP mRNA and protein expression and the trend toward a decrease of S100B protein expression levels.